NEW BAMBOO CONSULTING - Key Persons

Job Titles:

• Executive Assistant
• Project Coordinator

Ms. Holmon is an executive assistant and project coordinator with more than ten years' experience in healthcare and non-profit organizations at the corporate level. She has the ability to work well independently, but also as an integral team member in ever-changing environments. Ms. Holmon is very organized and able to bring order out of seeming chaos. Ms. Holmon worked at OneWorld Health (iOWH) with Ms. Cavani and Ms. Cheng. Ms. Holmon also worked with Ms. Cheng and Mr. Cassady at Bayer HealthCare. In addition to iOWH and Bayer HealthCare, Ms. Holmon has held positions at Genentech and Novartis, as well as other, non-healthcare related organizations.

Job Titles:

• Financial Analyst

Mr. Cassady is a financial analyst with more than 10 years of experience in strategic planning and financial controlling and 15 years experience in the biological pharmaceutical industry. He started his pharmaceutical career as a process development scientist, and has worked in manufacturing and quality administration, so he has a firm understanding of the science behind the products. He has designed and implemented site expansion projects from development of the project plan with both corporate partners and vendors, to working with leaders from the impacted departments to finalize design and assure post-implementation ownership by the various departments. His broad scientific and financial background has enabled him to analyze potential opportunities quickly, distill the analysis, and educate and make recommendations to senior management. He has been instrumental in developing business opportunities by careful analysis of licensing potential and leveraging novel technologies. Mr. Cassady holds a BA in Medical Biophysics from the University of California at Berkeley, and an MBA from St. Mary's College. James Cassady is a financial analyst with more than 10 years of experience in strategic planning and financial controlling and 15 years experience in the biological pharmaceutical industry. He has been instrumental in developing business opportunities by careful analysis of licensing potential and leveraging novel technologies. See full bio.

Ms. Cheng has over 20 years' experience in the corporate legal field, and an extensive background in international intellectual property. She has more than 5 years' experience in non-profits, including serving as the General Counsel and Vice President for Business Development for the Institute for OneWorld Health (iOWH), a non-profit pharmaceutical company and a product development partnership (PDP). She is a co-author of Socially Responsible Licensing. While at iOWH, she successfully established several private-public collaborations including: Semi-synthetic Artemisinin Project, iOWH/Roche Collaboration, iOWH/Novartis Collaboration and iOWH/Anacor Collaboration. Ms. Cheng has been a patent attorney for many years, writing and prosecuting patent applications, structuring corporate patent strategies, and supervising patent litigation. Her practice has encompassed myriad transactions involving patents, trade secrets and know-how licensing in many healthcare areas. This rare combination of skills and experience provides Ms. Cheng an unique advantage in crafting licensing and collaboration agreements. She has successfully negotiated many creative licensing arrangements, especially between non-profits and pharmaceutical companies. These licensing arrangements have varied in scope and content, but have provided the industry partner with patent rights for their primary indications while allowing the non-profit the ability to provide low-cost products to their target patients in developing countries. Prior to iOWH, Ms. Cheng spent nearly seven years with Bayer HealthCare, in both the Diagnostics and Biologicals Divisions. During her tenure at Bayer, she was part of the negotiating teams for many transactions, including: Sale of Innogenetics' LiPA HIV and LiPA HCV Tests, Exclusive Development and Supply Agreement for Diagnostic Sequencing and Bayer's Acquisition of Visible Genetics. Before joining Bayer, Ms. Cheng worked for Rohm and Haas Company and Alcon Laboratories, Inc., with a focus on international intellectual property. Ms. Cheng holds a JD from Franklin Pierce Law Center (now the University of New Hampshire Law School) and a BA in Chemistry from Reed College. She is a member of the New York, Pennsylvania and Texas bars, and is registered to practice before the US Patent & Trademark Office. Julie J.L. Cheng has over 20 years' experience in the corporate legal field, and an extensive background in international intellectual property. She has more than 5 years' experience in non-profits, including serving as the General Counsel and Vice President for Business Development for the Institute for OneWorld Health (iOWH), a non-profit pharmaceutical company and a product development partnership (PDP). She is a co-author on Socially Responsible Licensing. See full bio.

Ms. Fujii is a pharmaceutical regulatory compliance expert with more than 20 years' experience, and has an extensive background in international law. She has been a member of numerous global launch teams providing regulatory guidance relating to clinical trials, compassionate use programs, new drug applications, distribution, and commercial launch issues. See for example, XTANDI® (enzalutamide) for Patients With Metastatic Castration-Resistant Prostate Cancer, OMONTYS® (peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease (CKD) in Adult Patients on Dialysis, and Korlym™ (mifepristone) for Cushing's Syndrome Patients. Ms. Fujii spent 3 years as the Executive Director of the Academic Alliance for Infectious Diseases in Africa, a philanthropic project funded by Pfizer, Genentech, Cisco Systems and other companies to build the first outpatient HIV/AIDs clinic in western Africa designed to treat patients and train African doctors on HIV treatment and prevention. Prior to that, she spent 7 years at Pfizer working on international healthcare policy initiatives in South Africa, Israel, Japan, Australia, Taiwan, EU and other countries utilizing her experience as a FDA regulatory attorney. Projects included negotiations to update Japanese clinical trial regulations to accept clinical trials in non-Japanese subjects to comply with ICH standards. Before joining Pfizer, Ms. Fujii held positions with international responsibility in the legal departments of Merck & Co., Inc., and Schering-Plough Corporation. She was a member of the global development and launch teams for the drugs: XTANDI® (metastatic castration-resistant prostate cancer); VIBATIV® (complicated skin structure infections); VIAGRA® (erectile dysfunction); CRIXIVAN® (HIV/AIDS); PROSCAR® (benign prostatic hyperplasia); and FOSAMAX® (osteoporosis). She began her legal career as an international trade and FDA regulatory attorney at the law firm of Weil, Gotshal & Manges in Washington, DC. Ms. Fujii holds a JD from Georgetown University Law Center and an AB from Stanford University. She is a licensed member of the New York and Washington, DC bars. Ms. Fujii is currently providing FDA regulatory compliance services to biotech start-up companies preparing to launch their first FDA-regulated drug or device. Naoko Fujii is a pharmaceutical regulatory compliance expert with more than 20 years' experience, and has an extensive background in international law. She spent 3 years as the Executive Director of the Academic Alliance for Infectious Diseases in Africa, a philanthropic project funded by Pfizer, Genentech, Cisco Systems and other companies to build the first outpatient HIV/AIDs clinic in western Africa designed to treat patients and train African doctors on HIV treatment and prevention. See full bio.